{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,27]],"date-time":"2026-08-27T10:10:31Z","timestamp":1787825431772,"version":"build-2784847793"},"reference-count":40,"publisher":"Springer Science and Business Media LLC","issue":"7","license":[{"start":{"date-parts":[[2025,6,23]],"date-time":"2025-06-23T00:00:00Z","timestamp":1750636800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2025,6,23]],"date-time":"2025-06-23T00:00:00Z","timestamp":1750636800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Dermatologie"],"published-print":{"date-parts":[[2025,7]]},"DOI":"10.1007\/s00105-025-05522-z","type":"journal-article","created":{"date-parts":[[2025,6,23]],"date-time":"2025-06-23T11:33:01Z","timestamp":1750678381000},"page":"449-458","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":4,"title":["Pyoderma gangraenosum: Pathogenese, Diagnostik und Therapie","Pyoderma gangrenosum: pathogenesis, diagnosis, and treatment"],"prefix":"10.1007","volume":"76","author":[{"given":"Joachim","family":"Dissemond","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maurice","family":"Moelleken","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alpaslan","family":"Tasdogan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,6,23]]},"reference":[{"key":"5522_CR1","first-page":"290","volume":"25","author":"L Brocq","year":"1908","unstructured":"Brocq\u00a0L, Simon\u00a0CL (1908) Conrtibution a\u00a0l\u2019etude du phagedenisme. Bull Soc Med Hosp 25:290\u2013307","journal-title":"Bull Soc Med Hosp"},{"key":"5522_CR2","doi-asserted-by":"publisher","first-page":"1255","DOI":"10.1111\/iwj.13389","volume":"17","author":"MM Hobbs","year":"2020","unstructured":"Hobbs\u00a0MM, Ortega-Loayza\u00a0AG (2020) Pyoderma gangrenosum: from historical perspectives to emerging investigations. Int Wound\u00a0J 17:1255\u20131265","journal-title":"Int Wound J"},{"key":"5522_CR3","doi-asserted-by":"publisher","first-page":"81","DOI":"10.1038\/s41572-020-0213-x","volume":"6","author":"E Maverakis","year":"2020","unstructured":"Maverakis\u00a0E, Marzano\u00a0AV, Le\u00a0ST et\u00a0al (2020) Pyoderma gangrenosum. Nat Rev Dis Primers 6:81","journal-title":"Nat Rev Dis Primers"},{"key":"5522_CR4","doi-asserted-by":"publisher","first-page":"951","DOI":"10.1111\/iwj.12463","volume":"13","author":"F Jockenh\u00f6fer","year":"2012","unstructured":"Jockenh\u00f6fer\u00a0F, Klode\u00a0J, Kr\u00f6ger\u00a0K, Roesch\u00a0A, Al Ghazal\u00a0P, Dissemond\u00a0J (2012) Patients with pyoderma gangrenosum \u2212 analyses of the German DRG data from 2012. Int Wound\u00a0J 13:951\u2013956","journal-title":"Int Wound J"},{"key":"5522_CR5","doi-asserted-by":"publisher","first-page":"14876","DOI":"10.1111\/exd.14876","volume":"33","author":"SN Sanchez-Melendez","year":"2024","unstructured":"Sanchez-Melendez\u00a0SN, Malik\u00a0R, Patel\u00a0PM, Milosavljevic\u00a0S, Patel\u00a0S, Nambudiri\u00a0VE (2024) Pyoderma gangrenosum and impact on quality of life: a\u00a0narrative review. Exp Dermatol 33:14876","journal-title":"Exp Dermatol"},{"key":"5522_CR6","doi-asserted-by":"publisher","first-page":"1980","DOI":"10.3389\/fimmu.2017.01980","volume":"8","author":"EA Wang","year":"2018","unstructured":"Wang\u00a0EA, Steel\u00a0A, Luxardi\u00a0G et\u00a0al (2018) Classic ulcerative pyoderma gangrenosum is a\u00a0T\u00a0cell-mediated disease targeting follicular adnexal structures: a\u00a0hypothesis based on molecular and clinicopathologic studies. Front Immunol 8:1980","journal-title":"Front Immunol"},{"key":"5522_CR7","doi-asserted-by":"publisher","first-page":"4227","DOI":"10.1111\/iwj.14323","volume":"20","author":"M Moelleken","year":"2023","unstructured":"Moelleken\u00a0M, Erfurt-Berge\u00a0C, Ronicke\u00a0M et\u00a0al (2023) Predilection sites of pyoderma gangrenosum: retrospective study of 170 clearly diagnosed patients. Int Wound\u00a0J 20:4227\u20134234","journal-title":"Int Wound J"},{"key":"5522_CR8","doi-asserted-by":"publisher","first-page":"479","DOI":"10.1007\/s40257-018-0356-7","volume":"19","author":"K Kridin","year":"2018","unstructured":"Kridin\u00a0K, Cohen\u00a0AD, Amber\u00a0KT (2018) Underlying systemic diseases in pyoderma gangrenosum: a\u00a0systematic review and meta-analysis. Am J Clin Dermatol 19:479\u2013487","journal-title":"Am J Clin Dermatol"},{"key":"5522_CR9","doi-asserted-by":"publisher","first-page":"569","DOI":"10.1007\/s00105-008-1654-4","volume":"60","author":"J Klode","year":"2009","unstructured":"Klode\u00a0J, K\u00f6rber\u00a0A, Dissemond\u00a0J (2009) Psoriasis vulgaris als Trigger eines superfiziellen multilokul\u00e4ren Pyoderma gangraenosum? Hautarzt 60:569\u2013572","journal-title":"Hautarzt"},{"key":"5522_CR10","doi-asserted-by":"publisher","DOI":"10.1016\/j.jid.2024.09.023","author":"SL Becker","year":"2025","unstructured":"Becker\u00a0SL, Vague\u00a0M, Ortega-Loayza\u00a0AG (2025) Insights into the pathogenesis of pyoderma gangrenosum. J\u00a0Invest Dermatol. https:\/\/doi.org\/10.1016\/j.jid.2024.09.023","journal-title":"J Invest Dermatol"},{"key":"5522_CR11","doi-asserted-by":"publisher","first-page":"48","DOI":"10.1186\/1479-5876-4-48","volume":"4","author":"AM Lewis","year":"2006","unstructured":"Lewis\u00a0AM, Varghese\u00a0S, Xu\u00a0H, Alexander\u00a0HR (2006) Interleukin\u20111 and cancer progression: the emerging role of interleukin\u20111 receptor antagonist as a\u00a0novel therapeutic agent in cancer treatment. J\u00a0Transl Med 4:48","journal-title":"J Transl Med"},{"key":"5522_CR12","doi-asserted-by":"publisher","first-page":"960","DOI":"10.1111\/j.1365-2133.2007.08211.x","volume":"157","author":"TN Brooklyn","year":"2007","unstructured":"Brooklyn\u00a0TN, Williams\u00a0AM, Dunnill\u00a0MG, Probert\u00a0CS (2007) T\u2011cell receptor repertoire in pyoderma gangrenosum: evidence for clonal expansions and trafficking. Br J Dermatol 157:960\u2013966","journal-title":"Br J Dermatol"},{"key":"5522_CR13","doi-asserted-by":"publisher","first-page":"67","DOI":"10.1007\/s40257-017-0308-7","volume":"19","author":"JY Wang","year":"2018","unstructured":"Wang\u00a0JY, French\u00a0LE, Shear\u00a0NH, Amiri\u00a0A, Alavi\u00a0A (2018) Drug-induced pyoderma gangrenosum: a\u00a0review. Am J Clin Dermatol 19:67\u201377","journal-title":"Am J Clin Dermatol"},{"key":"5522_CR14","doi-asserted-by":"publisher","first-page":"615","DOI":"10.1111\/bjd.16401","volume":"180","author":"F Jockenh\u00f6fer","year":"2019","unstructured":"Jockenh\u00f6fer\u00a0F, Wollina\u00a0U, Salva\u00a0KA, Benson\u00a0S, Dissemond\u00a0J (2019) The PARACELSUS score: a\u00a0novel diagnostic tool for pyoderma gangrenosum. Br J Dermatol 180:615\u2013620","journal-title":"Br J Dermatol"},{"key":"5522_CR15","doi-asserted-by":"publisher","first-page":"866","DOI":"10.1111\/bjd.18003","volume":"181","author":"J Gottlieb","year":"2019","unstructured":"Gottlieb\u00a0J, Madrange\u00a0M, Gardair\u00a0C et\u00a0al (2019) PAPASH, PsAPASH and PASS autoinflammatory syndromes: phenotypic heterogeneity, common biological signature and response to immunosuppressive regimens. Br J Dermatol 181:866\u2013869","journal-title":"Br J Dermatol"},{"key":"5522_CR16","doi-asserted-by":"publisher","first-page":"1141","DOI":"10.1016\/j.jid.2020.08.028","volume":"141","author":"G Boursier","year":"2021","unstructured":"Boursier\u00a0G, Piram\u00a0M, Rittore\u00a0C, Sarrabay\u00a0G, Touitou\u00a0I (2021) Phenotypic associations of PSTPIP1 sequence variants in PSTPIP1-associated autoinflammatory diseases. J\u00a0Invest Dermatol 141:1141\u20131147","journal-title":"J Invest Dermatol"},{"key":"5522_CR17","first-page":"1003","volume":"21","author":"J Dissemond","year":"2023","unstructured":"Dissemond\u00a0J, Protz\u00a0K, St\u00fccker\u00a0M (2023) Kompressionstherapie in der Dermatologie. J\u00a0Dtsch Dermatol Ges 21:1003\u20131020","journal-title":"J Dtsch Dermatol Ges"},{"key":"5522_CR18","doi-asserted-by":"publisher","first-page":"1014","DOI":"10.3390\/jcm14031014","volume":"14","author":"D Didona","year":"2025","unstructured":"Didona\u00a0D, Rallo\u00a0A, Carugno\u00a0A, Paolino\u00a0G (2025) Paraneoplastic dermatoses: a\u00a0clue for underlying malignancies. J\u00a0Clin Med 14:1014","journal-title":"J Clin Med"},{"key":"5522_CR19","doi-asserted-by":"publisher","first-page":"268","DOI":"10.1007\/s00403-024-03098-7","volume":"316","author":"V Saeidi","year":"2024","unstructured":"Saeidi\u00a0V, Garimella\u00a0V, Shaji\u00a0K et\u00a0al (2024) Monoclonal gammopathy in the setting of pyoderma gangrenosum. Arch Dermatol Res 316:268","journal-title":"Arch Dermatol Res"},{"key":"5522_CR20","doi-asserted-by":"publisher","first-page":"2247","DOI":"10.1007\/s00277-019-03732-9","volume":"98","author":"AS Gupta","year":"2019","unstructured":"Gupta\u00a0AS, Ortega-Loayza\u00a0AG (2019) Pyoderma gangrenosum: a\u00a0too often overlooked facultative paraneoplastic disease. Ann Hematol 98:2247\u20132248","journal-title":"Ann Hematol"},{"key":"5522_CR21","doi-asserted-by":"publisher","first-page":"1412","DOI":"10.1056\/NEJMoa013383","volume":"347","author":"RH Weenig","year":"2002","unstructured":"Weenig\u00a0RH, Davis\u00a0MD, Dahl\u00a0PR, Su\u00a0WP (2002) Skin ulcers misdiagnosed as pyoderma gangrenosum. N\u00a0Engl J Med 347:1412\u20131418","journal-title":"N Engl J Med"},{"key":"5522_CR22","doi-asserted-by":"publisher","first-page":"59","DOI":"10.1016\/j.jid.2020.04.019","volume":"141","author":"C Haag","year":"2021","unstructured":"Haag\u00a0C, Hansen\u00a0T, Hajar\u00a0T et\u00a0al (2021) Comparison of three diagnostic frameworks for pyoderma gangrenosum. J\u00a0Invest Dermatol 141:59\u201363","journal-title":"J Invest Dermatol"},{"key":"5522_CR23","doi-asserted-by":"publisher","DOI":"10.1007\/s40257-025-00941-z","author":"SL Becker","year":"2025","unstructured":"Becker\u00a0SL, Badawi\u00a0AH, Thornton\u00a0C, Ortega-Loayza\u00a0AG (2025) Clinical mimickers misdiagnosed as pyoderma gangrenosum. Am J Clin Dermatol. https:\/\/doi.org\/10.1007\/s40257-025-00941-z","journal-title":"Am J Clin Dermatol"},{"key":"5522_CR24","first-page":"733","volume":"121","author":"J Dissemond","year":"2024","unstructured":"Dissemond\u00a0J, Placke\u00a0JM, Moelleken\u00a0M, Kr\u00f6ger\u00a0K (2024) The differential diagnosis of leg ulcers. Dtsch \u00c4rztebl Int 121:733\u2013739","journal-title":"Dtsch \u00c4rztebl Int"},{"key":"5522_CR25","doi-asserted-by":"publisher","first-page":"108","DOI":"10.1111\/jdv.16034","volume":"34","author":"VR Barton","year":"2020","unstructured":"Barton\u00a0VR, Le\u00a0ST, Wang\u00a0JZ, Toussi\u00a0A, Sood\u00a0A, Maverakis\u00a0E (2020) Peristomal ulcers misdiagnosed as pyoderma gangrenosum: a\u00a0common error. J\u00a0Eur Acad Dermatol Venereol 34:108\u2013110","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"5522_CR26","doi-asserted-by":"publisher","first-page":"1255","DOI":"10.1007\/s40265-023-01931-3","volume":"83","author":"J Dissemond","year":"2023","unstructured":"Dissemond\u00a0J, Marzano\u00a0AV, Hampton\u00a0PJ, Ortega-Loayza\u00a0AG (2023) Pyoderma gangrenosum: treatment options. Drugs 83:1255\u20131267","journal-title":"Drugs"},{"issue":"4","key":"5522_CR27","doi-asserted-by":"publisher","first-page":"317","DOI":"10.1111\/ddg.12585","volume":"13","author":"P Al Ghazal","year":"2015","unstructured":"Al Ghazal\u00a0P, Dissemond\u00a0J (2015) Therapy of pyoderma gangrenosum in Germany: results of a\u00a0survey among wound experts. J\u00a0Dtsch Dermatol Ges 13(4):317\u2013324","journal-title":"J Dtsch Dermatol Ges"},{"key":"5522_CR28","doi-asserted-by":"publisher","first-page":"2958","DOI":"10.1136\/bmj.h2958","volume":"350","author":"AD Ormerod","year":"2015","unstructured":"Ormerod\u00a0AD, Thomas\u00a0KS, Craig\u00a0FE et\u00a0al (2015) Comparison of the two most commonly used treatments for pyoderma gangrenosum: results of the STOP GAP randomised controlled trial. BMJ 350:2958","journal-title":"BMJ"},{"key":"5522_CR29","doi-asserted-by":"publisher","first-page":"139","DOI":"10.1007\/s40257-024-00904-w","volume":"26","author":"M Ronicke","year":"2025","unstructured":"Ronicke\u00a0M, Sollfrank\u00a0L, Vitus\u00a0MV et\u00a0al (2025) Intravenous immunoglobulin therapy for pyoderma gangrenosum: a\u00a0multicenter retrospective analysis in 81\u00a0patients. Am J Clin Dermatol 26:139\u2013146","journal-title":"Am J Clin Dermatol"},{"key":"5522_CR30","doi-asserted-by":"publisher","first-page":"505","DOI":"10.1136\/gut.2005.074815","volume":"55","author":"TN Brooklyn","year":"2006","unstructured":"Brooklyn\u00a0TN, Dunnill\u00a0MG, Shetty\u00a0A et\u00a0al (2006) Infliximab for the treatment of pyoderma gangrenosum: a\u00a0randomised, double blind, placebo controlled trial. Gut 55:505\u2013509","journal-title":"Gut"},{"key":"5522_CR31","doi-asserted-by":"publisher","first-page":"479","DOI":"10.1111\/1346-8138.16337","volume":"49","author":"K Yamasaki","year":"2022","unstructured":"Yamasaki\u00a0K, Yamanaka\u00a0K, Zhao\u00a0Y et\u00a0al (2022) Adalimumab in Japanese patients with active ulcers of pyoderma gangrenosum: final analysis of a\u00a052-week phase\u00a03 open-label study. J\u00a0Dermatol 49:479\u2013487","journal-title":"J Dermatol"},{"key":"5522_CR32","doi-asserted-by":"publisher","first-page":"29","DOI":"10.1080\/17512433.2024.2447776","volume":"8","author":"H Keum","year":"2025","unstructured":"Keum\u00a0H, Zhivov\u00a0EV, Ortega-Loayza\u00a0AG (2025) Updates in innovation of the treatment of pyoderma gangrenosum. Expert Rev Clin Pharmacol 8:29\u201339","journal-title":"Expert Rev Clin Pharmacol"},{"key":"5522_CR33","doi-asserted-by":"publisher","first-page":"733","DOI":"10.1007\/s00105-021-04858-6","volume":"72","author":"J Dissemond","year":"2021","unstructured":"Dissemond\u00a0J (2021) Modernes Management chronischer Wunden. Hautarzt 72:733\u2013744","journal-title":"Hautarzt"},{"key":"5522_CR34","doi-asserted-by":"publisher","first-page":"369","DOI":"10.1007\/s00105-022-04944-3","volume":"73","author":"J Dissemond","year":"2022","unstructured":"Dissemond\u00a0J, B\u00fcltemann\u00a0A, Gerber\u00a0V, Motzkus\u00a0M, M\u00fcnter\u00a0KC, Erfurt-Berge\u00a0C (2022) Positionspapier der Initiative Chronische Wunde (ICW) e.\u202fV. zur Nomenklatur des D\u00e9bridements chronischer Wunden. Hautarzt 73:369\u2013375","journal-title":"Hautarzt"},{"key":"5522_CR35","doi-asserted-by":"publisher","first-page":"70135","DOI":"10.1111\/iwj.70135","volume":"21","author":"A Haroon","year":"2024","unstructured":"Haroon\u00a0A, Gillespie\u00a0J, Roland-McGowan\u00a0J et\u00a0al (2024) Local wound care management for pyoderma gangrenosum. Int Wound\u00a0J 21:70135","journal-title":"Int Wound J"},{"key":"5522_CR36","doi-asserted-by":"publisher","DOI":"10.1111\/ddg.15649","author":"J Dissemond","year":"2025","unstructured":"Dissemond\u00a0J, Rembe\u00a0JD, Assenheimer\u00a0B et\u00a0al (2025) Systematics, diagnosis and treatment of wound infections in chronic wounds: a\u00a0position paper from WundDACH. J\u00a0Dtsch Dermatol Ges. https:\/\/doi.org\/10.1111\/ddg.15649","journal-title":"J Dtsch Dermatol Ges"},{"key":"5522_CR37","doi-asserted-by":"publisher","first-page":"13412","DOI":"10.1111\/dth.13412","volume":"33","author":"A Janowska","year":"2020","unstructured":"Janowska\u00a0A, Oranges\u00a0T, Fissi\u00a0A, Davini\u00a0G, Romanelli\u00a0M, Dini\u00a0V (2020) PG-TIME: a\u00a0practical approach to the clinical management of pyoderma gangrenosum. Dermatol Ther 33:13412","journal-title":"Dermatol Ther"},{"issue":"4","key":"5522_CR38","doi-asserted-by":"publisher","first-page":"280","DOI":"10.1007\/s00105-011-2141-x","volume":"62","author":"L Huptas","year":"2011","unstructured":"Huptas\u00a0L, Rompoti\u00a0N, Herbig\u00a0S et\u00a0al (2011) Schmerzreduktion bei Patienten mit chronischem Ulcus cruris durch ein neu entwickeltes Morphingel. Hautarzt 62(4):280\u2013286","journal-title":"Hautarzt"},{"key":"5522_CR39","doi-asserted-by":"publisher","first-page":"1274","DOI":"10.1001\/jamadermatol.2023.3115","volume":"159","author":"KM Erickson","year":"2023","unstructured":"Erickson\u00a0KM, Kody\u00a0S, Ortega-Loayza\u00a0AG (2023) Pain as a\u00a0patient-reported outcome measure in pyoderma gangrenosum. JAMA Dermatol 159:1274\u20131275","journal-title":"JAMA Dermatol"},{"key":"5522_CR40","doi-asserted-by":"publisher","first-page":"2166","DOI":"10.1038\/jid.2012.130","volume":"132","author":"SM Langan","year":"2013","unstructured":"Langan\u00a0SM, Groves\u00a0RW, Card\u00a0TR, Gulliford\u00a0MC (2013) Incidence, mortality, and disease associations of pyoderma gangrenosum in the United Kingdom: a\u00a0retrospective cohort study. J\u00a0Invest Dermatol 132:2166\u20132170","journal-title":"J Invest Dermatol"}],"container-title":["Die Dermatologie"],"original-title":[],"language":"de","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00105-025-05522-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00105-025-05522-z\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00105-025-05522-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,7,3]],"date-time":"2025-07-03T08:36:31Z","timestamp":1751531791000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00105-025-05522-z"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,6,23]]},"references-count":40,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2025,7]]}},"alternative-id":["5522"],"URL":"https:\/\/doi.org\/10.1007\/s00105-025-05522-z","relation":{},"ISSN":["2731-7005","2731-7013"],"issn-type":[{"value":"2731-7005","type":"print"},{"value":"2731-7013","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,6,23]]},"assertion":[{"value":"22 May 2025","order":1,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"23 June 2025","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Einhaltung ethischer Richtlinien"}},{"value":"Gem\u00e4\u00df den Richtlinien des Springer Medizin Verlags werden Autoren und Wissenschaftliche Leitung im Rahmen der Manuskripterstellung und Manuskriptfreigabe aufgefordert, eine vollst\u00e4ndige Erkl\u00e4rung zu ihren finanziellen und nichtfinanziellen Interessen abzugeben.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Interessenkonflikt"}},{"value":"J.\u00a0Dissemond: A.\u00a0Finanzielle Interessen: Finanzielle Leistungen f\u00fcr klinische Forschungsprojekte: med, M\u00f6lnlycke, Urgo, InflaRx, Novartis, Boehringer Ingelheim, Hartmann, Convatec, Piomic. \u2013\u00a0Honorare als Referent: Lilly, Hartmann, Curea, Integra, Convatec, Coloplast, Juzo, Infectopharm, UCB, M\u00f6lnlycke, Urgo.\u00a0\u2013 Honorare als Referent: Smith\u00a0& Nephew, Merieux, Convatec, Urgo, M\u00f6lnlycke, Novartis, Hartmann, Integra, Aurealis, Engelhardt, Flen Pharma, 3M. \u2013\u00a0B. Nichtfinanzielle Interessen: Oberarzt in der Klinik f\u00fcr Dermatologie, Venerologie und Allergologie im Universit\u00e4tsklinikum Essen | Vorstandsmitglied bei folgenden Fachgesellschaften: Initiative Chronische Wunden (ICW) e.\u202fV., Arbeitsgemeinschaft Wundheilung (AGW) der Deutschen Dermatologischen Gesellschaft (DDG), WundDACH | Mitgliedschaften bei folgenden Fachgesellschaften: Deutsche Gesellschaft f\u00fcr Phlebologie und Lymphologie (DGPL), Deutscher Wundrat, Europ\u00e4ische Wundheilungsorganisation (EWMA). A.\u00a0Tasdogan: A.\u00a0Finanzielle Interessen: Vortrag f\u00fcr BMS, Danone und Merck Sharp\u00a0& Dohme.\u00a0\u2013 B. Nichtfinanzielle Interessen: T\u00e4tigkeit: Univ.-Professor und Oberarzt, Universit\u00e4tsklinikum Essen | Vorstand: Arbeitsgemeinschaft Dermatologische Forschung (ADF). M.\u00a0Moelleken: A.\u00a0Finanzielle Interessen: BMBF (Bundesministerium f\u00fcr Bildung und Forschung), DFG (Deutsche Forschungsgemeinschaft). \u2013\u00a0Vortragshonorare oder Kostenerstattung als passiv Teilnehmender: Adtec Healthcare, BGM Forum Westm\u00fcnsterland, MedKom Akademie, M\u00f6lnlycke Health Care, Rheacell, Urgo.\u00a0\u2013 B. Nichtfinanzielle Interessen: Assistenzarzt in der Klinik und Poliklinik f\u00fcr Dermatologie, Venerologie und Allergologie (Universit\u00e4tsklinikum Essen).","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Autoren"}},{"value":"Die vollst\u00e4ndige Erkl\u00e4rung zum Interessenkonflikt der Wissenschaftlichen Leitung finden Sie am Kurs der zertifizierten Fortbildung auf .","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Wissenschaftliche Leitung"}},{"value":"erkl\u00e4rt, dass f\u00fcr die Publikation dieser CME-Fortbildung keine Sponsorengelder an den Verlag flie\u00dfen.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Der Verlag"}},{"value":"F\u00fcr diesen Beitrag wurden von den Autor\/-innen keine Studien an Menschen oder Tieren durchgef\u00fchrt. F\u00fcr die aufgef\u00fchrten Studien gelten die jeweils dort angegebenen ethischen Richtlinien. F\u00fcr Bildmaterial oder anderweitige Angaben innerhalb des Manuskripts, \u00fcber die Patient\/-innen zu identifizieren sind, liegt von ihnen und\/oder ihren gesetzlichen Vertretern\/Vertreterinnen eine schriftliche Einwilligung vor.","order":6,"name":"Ethics","group":{"name":"EthicsHeading","label":"Der Verlag"}}]}}